Corneal inlay proves safe, effective and reversible option for presbyopes

Article

The KAMRA inlay (AcuFocus) is an effective, safe and reversible technique for the long-term surgical treatment of presbyopia.

The KAMRA inlay (AcuFocus) is an effective, safe and reversible technique for the long-term surgical treatment of presbyopia, states a 4-year follow-up study featured in the Journal of Cataract and Refractive Surgery.

Dr O.F. Yilmaz et al., Beyoğlu Eye Training and Research Hospital, Istanbul, Turkey, developed a clinical trial including 39 presbyopic phakic patients aged 45 to 60 years. Patients had an initial uncorrected near visual acuity (UNVA) of 20/40 or worse, this was correctable to 20/25 or better at distance.

After the LASIK flap was created or relifted the KAMRA inlay was implanted on the stromal bed and centred on the presurgical position of the first Purkinje reflex. Distance and near vision and the complication rate were measured.

It was found that 5 patients experienced cataract progression, 2 had a change in refractive status and there were no severe corneal complications or intraoperative complications during cataract extraction.

At a mean final UNVA of 20/20 all patients demonstrated an improvement in UNVA of 2 lines or more- with minimum loss in distance vision. In all eyes uncorrected distance acuity was 20/40 or better and it was recorded that 96% of patients could read J3 or better.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.